David Neidhardt, MD
Family Medicine · Lima, OHNPI 1396797510
Payments from drug & device makers
Across 538 payments — averaging $461.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$212K
- Shire North American Group Inc$32K
- AbbVie$919
- Novo Nordisk$664
- Boehringer Ingelheim$403
- AstraZeneca$373
- plus $3K from 32 others
What the payments were for
- Consulting fees$242,01398%
- Travel & lodging$1,1580%
- Food & beverage$4,9872%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$248,173 in reported general payments places this provider in the 95th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 111 | $122,170 |
| MounjaroTirzepatide | 76 | $88,346 |
| TrulicityDulaglutide | 54 | $75,080 |
| OzempicSemaglutide | 58 | $72,696 |
| EliquisApixaban | 119 | $71,188 |
| FarxigaDapagliflozin Propanediol | 26 | $39,717 |
| RybelsusSemaglutide | 14 | $27,886 |
| Repatha SureclickEvolocumab | 15 | $10,554 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $8,672 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $7,358 |
| MyrbetriqMirabegron | 20 | $7,208 |
| SynthroidLevothyroxine Sodium | 106 | $6,652 |
| Atorvastatin Calcium | 477 | $5,035 |
| Rosuvastatin Calcium | 296 | $3,990 |
| Metoprolol Succinate | 180 | $3,006 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $293 | $163,425130 claims |
| Boehringer IngelheimJardiance | $403 | $122,170111 claims |
| Novo NordiskOzempic, Rybelsus | $664 | $100,58272 claims |
| PfizerEliquis | $197 | $71,188119 claims |
| AstraZenecaFarxiga | $373 | $39,71726 claims |
| GSKTrelegy Ellipta | $105 | $8,67212 claims |
| Astellas Pharma US IncMyrbetriq | $65 | $7,20820 claims |
| AbbVieSynthroid | $919 | $6,652106 claims |
| Sanofi-aventis U.S. LLCLantus | $150 | $2,62615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Lima
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.